Memantine in moderate-to-severe Alzheimer's disease.

BACKGROUND Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease. METHODS Patients with moderate-to-severe Alzheimer's disease were randomly assigned to receive placebo or 20 mg of memantine daily for 28 weeks. The primary efficacy variables were the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) and the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADLsev). The secondary efficacy end points included the Severe Impairment Battery and other measures of cognition, function, and behavior. Treatment differences between base line and the end point were assessed. Missing observations were imputed by using the most recent previous observation (the last observation carried forward). The results were also analyzed with only the observed values included, without replacing the missing values (observed-cases analysis). RESULTS Two hundred fifty-two patients (67 percent women; mean age, 76 years) from 32 U.S. centers were enrolled. Of these, 181 (72 percent) completed the study and were evaluated at week 28. Seventy-one patients discontinued treatment prematurely (42 taking placebo and 29 taking memantine). Patients receiving memantine had a better outcome than those receiving placebo, according to the results of the CIBIC-Plus (P=0.06 with the last observation carried forward, P=0.03 for observed cases), the ADCS-ADLsev (P=0.02 with the last observation carried forward, P=0.003 for observed cases), and the Severe Impairment Battery (P<0.001 with the last observation carried forward, P=0.002 for observed cases). Memantine was not associated with a significant frequency of adverse events. CONCLUSIONS Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.

[1]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[2]  R. Katzman.,et al.  Pathological verification of ischemic score in differentiation of dementias , 1980, Annals of neurology.

[3]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[4]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[5]  F. Fonnum.  Glutamate: A Neurotransmitter in Mammalian Brain , 1984, Journal of neurochemistry.

[6]  B. Reisberg.  Functional assessment staging (FAST). , 1988, Psychopharmacology bulletin.

[7]  G. Koch,et al.  The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials , 1991 .

[8]  B. Reisberg,et al.  Functional Assessment Staging (FAST) in Alzheimer's Disease: Reliability, Validity, and Ordinality , 1992, International Psychogeriatrics.

[9]  F. Orrego,et al.  The chemical nature of the main central excitatory transmitter: A critical appraisal based upon release studies and synaptic vesicle localization , 1993, Neuroscience.

[10]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[11]  S. Lipton,et al.  Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.

[12]  F. Boller,et al.  Severe impairment battery. A neuropsychological test for severely demented patients. , 1994, Archives of neurology.

[13]  L. Margulis,et al.  Swimming against the current. , 1997, The Sciences.

[14]  L. Schneider,et al.  The Severe Impairment Battery: Concurrent Validity and the Assessment of Longitudinal Change in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.

[15]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.

[16]  B. Reisberg,et al.  Report of an International Psychogeriatric Association Special Meeting Work Group; Under the Cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association , 1997, International Psychogeriatrics.

[17]  A R Dobbs,et al.  Evaluating the Driving Competence of Dementia Patients , 1997, Alzheimer disease and associated disorders.

[18]  J. Newcomer,et al.  The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. , 1998, Progress in brain research.

[19]  B. Winblad,et al.  Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.

[20]  C. Shaw,et al.  Glutamate Slows Axonal Transport of Neurofilaments in Transfected Neurons , 2000, The Journal of cell biology.

[21]  M. Sano,et al.  Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease , 2000, Neurobiology of Aging.

[22]  E. Shimizu,et al.  NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation. , 2000, Science.

[23]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[24]  Anthony F. Jorm,et al.  Definition and Epidemiology of Dementia: A Review , 2003 .